Abexinostat (formerly PCI-24781) is a new broad-spectrum hydroxamate-based HDAC inhibitor that affects chromatin organization and gene transcription in MCL and induces apoptosis in lymphoma cell lines in a caspase and reactive oxygen species-dependent mechanisms [124, 125]. Here, HDAC9 is linked to mantle cell lymphoma.